RevenanasBook a free audit

Layoffs

Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot

Biotech

Layoffs

Key Facts

Signal Type

Layoffs

Industry

Biotech

Companies

Molecular Partners, Novartis, Amgen, Zai Lab

Date

What Happened

Molecular Partners, a Zurich-based biotech, announced plans to lay off up to 44% of its workforce, affecting up to 55 positions. The restructuring is part of a strategic pivot to focus the company's declining cash reserves on its radiotherapeutic pipeline. The company expects to implement the changes by the second quarter of 2027, with the full cost reduction effects felt in the second half of that year.

Who Is Affected

The layoffs will impact up to 55 employees across the organization. Molecular Partners is consulting with employees as required under Swiss law. The company is prioritizing its phase 1/2a study of MP0712, a DLL3-targeting radiopharmaceutical for small cell lung cancer, and advancing its broader "Radio-DARPin" pipeline. Other programs, including the multispecific T-cell engager MP0533 and the bispecific MP0317, are being deprioritized as the company shifts focus exclusively to radiopharmaceuticals, with plans to explore immune cell engagers through strategic partnerships and spinout opportunities.

Market Impact

  • Narrowed pipeline: Molecular Partners is concentrating resources on a single lead candidate (MP0712) and two earlier-stage programs (MP0726, MP0730), creating urgency for partnerships and operational efficiency.
  • Cash runway: With $69 million in cash reserves funding operations into late 2027, the company is under pressure to demonstrate value from its radiotherapy pivot, making it a target for CROs, clinical trial management platforms, and biotech ops software vendors.
  • Competitive landscape: MP0712 targets DLL3, the same target as Amgen's Imdelltra and Zai Lab's zocilurtatug pelitecan, positioning Molecular Partners in a competitive but validated space.

What to Watch

Key milestones include initial safety data from the MP0712 phase 1/2a study expected in December 2026, with efficacy results following in 2027. The second radiopharmaceutical program, MP0726, is advancing to first-in-human imaging in the second half of 2026, and MP0730 could enter first-in-human studies in mid-2027. Additionally

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner